Cantargia (Cantargia AB); today announced new clinical results from two nadunolimab combination therapy trials in 54 patients. Positive signals of efficacy were documented in the key areas of ...
The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...
Peripheral neuropathy encompasses a variety of conditions marked by damage or lesions to peripheral nerves, resulting in symptoms such as pain, itch, and sensory disturbances. Diseases such as ...
Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...